Fort Lauderdale, FL-September 30, 2009
In a multi-year enterprise-wide agreement Kendle will add OmniComm’s TrialMaster EDC solution to its current eClinical offerings.
“Efficient delivery of high-quality data is critical to Kendle’s continued success as a leading provider of clinical data management services,” said John Fontenault, Executive Director and Global Head, Clinical Data Management and Technology. "The addition of the TrialMaster EDC solution to our existing offerings supports Kendle’s focus on providing our global biopharmaceutical customers with cost-effective access to the best eClinical solutions to accelerate their Phase I through IV clinical trials. The TrialMaster platform offers the right mix of functionality to streamline the study development process and drive efficient study operations.”
"We are excited to be working with Kendle to meet the needs of its diverse customer base," said Stephen Johnson, COO of OmniComm Systems. "Kendle is one of the largest and most respected and successful top-tier global CROs with extensive eClinical experience, having conducted more than 250 trials utilizing EDC technologies to expedite the clinical trials process. We look forward to providing them the eClinical solutions and services needed to support their continued delivery of best-in-class clinical development services to their customers.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.